Valeant faces PhRMA attack, will discuss fraud allegation

PhRMA posted an Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX), saying the company's "strategy is more reflective of a hedge fund than an innovative biopharmaceutical company." The article, by PhRMA SVP of Communications Robert Zirkelbach, contrasted Valeant's business model with those

Read the full 404 word article

How to gain access

Continue reading with a
two-week free trial.